General Information of Drug (ID: DMYJ9CF)

Drug Name
H-409/22 Drug Info
Synonyms Y1 receptor antagonist 1; AC1NSKN0; H-409/22; H 409-22; SCHEMBL1593464; CS-7270; HY-101704
Indication
Disease Entry ICD 11 Status REF
Cardiovascular disease BA00-BE2Z Discontinued in Phase 2 [1]
Cross-matching ID
PubChem CID
5311439
TTD Drug ID
DMYJ9CF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NEUROPEPTIDE-Y DMINQP1 N. A. N. A. Phase 2 [3]
PD-160170 DMB9Z4C Heart disease BA41-BA42 Preclinical [4]
GI-264879A DM25N8B Obesity 5B81 Preclinical [4]
SR 120819A DMETDFM Eating disorder 6B82 Terminated [5]
BIBP 3226 DMYBR9D Hypertension BA00-BA04 Terminated [6]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one DMM9X0G Discovery agent N.A. Investigative [7]
H-[Trp-Arg-Nva-Arg-Tyr]3-NH2 DMKH8PF Discovery agent N.A. Investigative [8]
Sub[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DM4SWQA Discovery agent N.A. Investigative [8]
Pim[-Trp-Arg-Nva-Arg-Tyr-NH2]2 DMBERSG Discovery agent N.A. Investigative [8]
Sub[-Tyr-Arg-Leu-Arg-Tyr-NH2]2 DM56MOV Discovery agent N.A. Investigative [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 1 (NPY1R) TTRK9JT NPY1R_HUMAN Antagonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013561)
2 In vivo characterization of the novel neuropeptide Y Y1 receptor antagonist H 409/22. J Cardiovasc Pharmacol. 2000 Oct;36(4):516-25.
3 5-OHKF and NorKA, depsipeptides from a Hawaiian collection of Bryopsis pennata: binding properties for NorKA to the human neuropeptide Y Y1 receptor. J Nat Prod. 2009 Dec;72(12):2172-6.
4 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
5 SR 120819A, an orally-active and selective neuropeptide Y Y1 receptor antagonist. FEBS Lett. 1995 Apr 3;362(2):192-6.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 305).
7 Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.
8 Neuropeptide Y (NPY) Y4 receptor selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective agonist with picomolar a... J Med Chem. 2006 Apr 20;49(8):2661-5.